12:00 AM
Nov 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Dihydroergotoxine-containing medicines regulatory update

EMA's CHMP maintained its previous recommendations on the use of medicines containing dihydroergotoxine following a re-examination requested by a manufacturer. In June, the committee recommended restricting the use of medicines containing ergot derivatives, including dihydroergotoxine, from treating several conditions involving blood circulation problems, problems with memory and sensation or to prevent migraines because the risks are greater...

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >